Amae Health raises $25m to scale AI-enabled outpatient care for severe mental illness

US-based mental health provider Amae Health has raised US$25m in pre-empted Series B financing to expand its AI-enabled outpatient clinics for people living with severe mental illness (SMI), taking total funding to more than US$50m.

The round was led by Altos Ventures, with participation from all existing investors, including Quiet Capital, Bling Capital, Cedars-Sinai Ventures, Healthier Capital and 8VC. The San Francisco-headquartered Public Benefit Corporation will use the capital to accelerate the opening of Amae clinics across the US, advance its proprietary AI-driven care platform and support research into schizophrenia, bipolar disorder and treatment-resistant depression.

Amae Health focuses on adults with SMI, a group that includes conditions such as schizophrenia, schizoaffective disorder and bipolar disorder and affects more than 15 million people in the US. Many of these patients cycle between emergency departments, inpatient units and fragmented community services, with little access to continuous, coordinated care. 

The company is positioning itself as an alternative to virtual-only or low-touch models, combining in-person psychiatry-led care with wraparound support and AI-powered clinical tools. Its multidisciplinary teams bring together psychiatrists, therapists, primary care clinicians, dietitians and social services specialists to deliver team-based outpatient care, with a focus on long-term engagement rather than episodic crisis management. 

“Severe mental illness devastates families and communities, yet traditional treatment models haven’t moved the needle,” said Stas Sokolin, co-founder and CEO of Amae Health. “Our north star is a true cure, defined as it is in oncology: five or more years of remission.” 

Founded in 2022, Amae opened its first clinic in Los Angeles and has since partnered with health systems including NewYork-Presbyterian, Cedars-Sinai and Stanford Health Care to bring its model into new markets. The company works with payers and providers to embed its clinics within local ecosystems, aiming to reduce readmissions, improve medication adherence and increase community stability for patients who are often high-cost, high-need users of the system. 

Its AI-driven platform sits behind the bricks-and-mortar clinics, aggregating patient data, clinical assessments and longitudinal outcomes to support measurement-based care and earlier identification of relapse risk. According to the company, this combination of technology and intensive, in-person support has delivered strong early results, including marked reductions in 30-day hospital readmissions compared with national benchmarks and significant improvements in symptom scores across mood, psychosis and suicidality, alongside high follow-up and satisfaction rates. 

To deepen its research and innovation capabilities, Amae has also launched the Amae Institute, described as a centre of excellence dedicated to advancing care for SMI. The institute works with academic medical centres and research hospitals to develop and test next-generation treatments, with the goal of moving the field towards long-term remission and, eventually, curative approaches.

With fresh Series B capital in place, the company plans to grow its clinic footprint, invest further in its AI platform and expand collaborations with leading health systems and universities. For payers and providers grappling with the clinical and economic burden of SMI, Amae is pitching its integrated, tech-enabled model as a scalable way to deliver more continuous, community-based care for some of the most complex patients in the behavioural health system.